Wolbachia-Laced Mosquitoes to Be Released for Population Control

The US government has approved the deployment of the lab-raised insects to eliminate the Zika- and dengue-transmitting Asian tiger mosquito.

Written byKatarina Zimmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Aedes albopictus ISTOCK, GORDZAMThe US Environmental Protection Agency (EPA) has given permission to a biotechnology startup to release mosquitoes into the environment that have been designed to eradicate wild populations of disease-carrying mosquitoes, Nature News reports.

The target is the Asian tiger mosquito Aedes albopictus, a vector for Zika virus—which began to spread in the U.S. last year—as well as dengue and yellow fever. The startup MosquitoMate has designed “killer” tiger mosquitoes by infecting males with the bacterium Wolbachia pipientis. When these treated males mate with wild female mosquitoes that don’t carry the same Wolbachia strain, the resulting eggs die.

According to Nature News, the EPA hasn’t officially announced the release of the insects yet, which will be limited to 20 states. These exclude the southeastern US states, despite harboring a greater concentration of mosquito populations, because field trials have not been conducted in those climates. Instead, the approved states are similar to New York, Kentucky, and California, where trials took ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies